Organization
Shanghai HEP Pharmaceutical
4 clinical trials
Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined With Pegylated Interferon in Subjects With Chronic Hepatitis BStatus: Completed, Estimated PCD: 2023-11-01
Clinical trial
A Randomized, Double-blind, Placebo-Controlled, Repeat-Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of L47 in Subjects With Type 2 Diabetes Mellitus on Stable MetforminStatus: Withdrawn, Estimated PCD: 2025-12-01
Clinical trial
A Phase II of Randomized, Double-blind, Placebo-controlled, Multi-center Study of Hepalatide for Injection Combined With Pegylated Interferon and TAF as Finite Treatment in Chronic Hepatitis B PatientsStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Double-blinded, Placebo-controlled, Munticenter, Phase IIa Clinical Trial of Hepalatide in Patients With Chronic Hepatitis DStatus: Completed, Estimated PCD: 2024-01-30